ODT

The Mouth Dissolving Drug Delivery Systems was an advancement that came into existence in the early 1970’s and combats over the use of the conventional tablets, syrups, capsules which are the other oral drug delivery systems. Orally disintegrating dosage forms can address the pharmaceutical needs of the paediatric and geriatric patient group having difficulties in swallowing the conventional solid oral dosage forms. Orally disintegrating dosage forms also have the advantage of self medication, pain avoidance hence better patient compliance. Taste masking of bitter drugs is an important parameter. Orally disintegrating dosage forms may have an added advantage of bypassing first pass metabolism. Acyclovir is an antiviral drug used for the treatment of herpes simplex virus (HSV), mainly HSV-1 and HSV-2 and varicella zoster virus. It is a BCS class III drug. Hence an orally disintegrating tablet formulation of acyclovir was prepared by direct compression techniques after incorporating superdisintegrants croscarmellose sodium , sodium starch glycolate and Crossprovidone . Eight formulations were prepared. Tablet containing sodium starch glycolate and croscarmellose sodium showed excellent in vitro dispersion time and drug release as compared to other formulation. After   study of eight formulations F8 showed short dispersion time with maximum drug release in 25 min. It is concluded that fast disintegrating acyclovir tablets could be prepared by direct compression using superdisintegrants.

Desloratadine is an antagonist at histamine H1 receptors, and an antagonist at all subtypes of the muscarinic acetylcholine receptor. It has a long-lasting effect and in moderate and low doses, does not cause drowsiness because it does not readily enter the central nervous system. The present study is an attempt to formulate and evaluate the fast dissolving tablets of  Desloratadine. Fast dissolving tablets were prepared by direct compression after masking the bitter taste of drug by solid dispersion method with the aid of superdisintegrants. Seven formulations were developed using two different superdisintegrants in varying concentrations in such a way that total weight of the tablet remains the same. The drug-polymer incompatibility was ruled out by FTIR studies. All the formulated tablets were subjected for pre and post-compression evaluation parameters. A comparison of in vitro drug release of best formulation along with F1 formulation having no superdisintegrants is carried out. All the formulated tablets were shown satisfactory results which complies with official limits. Among the seven formulations, F7 was selected as the best formulation as its wetting time was 33 seconds, disintegration time was 29 seconds and %CDR after 8 minutes was 100.1%. F7 was found to be stable at 25°C ± 2 °C,  60°C ± 5°C and 40 °C ± 2 °C and 75 ± 5 % RH . Formulated tablets containing high concentration of croscarmellose sodium are better and effective than conventional tablets to meet patient compliance, give fast relief from allergy and cost effective.